Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus

Double-blind Randomized Placebo-controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis

“…In addition, markers of glycemic control worsened in the PUFA treated patients while lipid control did not change. These data are in contrast to previous data on the analysis of 23 trials using omega 3 PUFA in type 2 diabetes mellitus (17). Plasma triglyceride levels decreased while glycemic control and HDL did not change.…”

Double-blind Randomized Placebo-controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis

“…In addition, markers of glycemic control worsened in the PUFA treated patients while lipid control did not change. These data are in contrast to previous data on the analysis of 23 trials using omega 3 PUFA in type 2 diabetes mellitus (17). Plasma triglyceride levels decreased while glycemic control and HDL did not change.…”

Serum level changes of long chain-polyunsaturated fatty acids in patients undergoing periodontal therapy combined with one year of omega-3 supplementation: a pilot randomized clinical trial

“…However, the test group showed a significant reduction in LDL level at T1, and increased insulin and glycated hemoglobin after 12 months. Our results are somewhat in agreement with previous studies that have reported an unfavorable effect or no effect of ω-3 PUFA on glucose metabolism [31,32]. Others have shown that DHA supplementation increases HDL and LDL, and reduces triglyceride [33,34].…”

Effect of n-3 (Omega-3) Polyunsaturated Fatty Acid Supplementation on Metabolic and Inflammatory Biomarkers and Body Weight in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of RCTs

“…We observed a significant reduction in triglycerides, total cholesterol, and LDL levels and significant increase in HDL level in response to n-3 supplementation in T2DM. These findings are similar to the results of previous meta-analyses [56][57][58][59]. Our sub-group analysis however also revealed that n-3 supplementation of greater than 1000 mg/d for more than 8 weeks can significantly improve the lipid profile in patients with T2DM.…”

Double-blind Randomized Placebo-controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis

“…In addition, markers of glycemic control worsened in the PUFA treated patients while lipid control did not change. These data are in contrast to previous data on the analysis of 23 trials using omega 3 PUFA in type 2 diabetes mellitus (17). Plasma triglyceride levels decreased while glycemic control and HDL did not change.…”

Serum level changes of long chain-polyunsaturated fatty acids in patients undergoing periodontal therapy combined with one year of omega-3 supplementation: a pilot randomized clinical trial

“…However, the test group showed a significant reduction in LDL level at T1, and increased insulin and glycated hemoglobin after 12 months. Our results are somewhat in agreement with previous studies that have reported an unfavorable effect or no effect of ω-3 PUFA on glucose metabolism [31,32]. Others have shown that DHA supplementation increases HDL and LDL, and reduces triglyceride [33,34].…”

Effect of n-3 (Omega-3) Polyunsaturated Fatty Acid Supplementation on Metabolic and Inflammatory Biomarkers and Body Weight in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of RCTs

“…We observed a significant reduction in triglycerides, total cholesterol, and LDL levels and significant increase in HDL level in response to n-3 supplementation in T2DM. These findings are similar to the results of previous meta-analyses [56][57][58][59]. Our sub-group analysis however also revealed that n-3 supplementation of greater than 1000 mg/d for more than 8 weeks can significantly improve the lipid profile in patients with T2DM.…”

Double-blind Randomized Placebo-controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis

“…In addition, markers of glycemic control worsened in the PUFA treated patients while lipid control did not change. These data are in contrast to previous data on the analysis of 23 trials using omega 3 PUFA in type 2 diabetes mellitus (17). Plasma triglyceride levels decreased while glycemic control and HDL did not change.…”

Serum level changes of long chain-polyunsaturated fatty acids in patients undergoing periodontal therapy combined with one year of omega-3 supplementation: a pilot randomized clinical trial

“…However, the test group showed a significant reduction in LDL level at T1, and increased insulin and glycated hemoglobin after 12 months. Our results are somewhat in agreement with previous studies that have reported an unfavorable effect or no effect of ω-3 PUFA on glucose metabolism [31,32]. Others have shown that DHA supplementation increases HDL and LDL, and reduces triglyceride [33,34].…”

Effect of n-3 (Omega-3) Polyunsaturated Fatty Acid Supplementation on Metabolic and Inflammatory Biomarkers and Body Weight in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of RCTs

“…We observed a significant reduction in triglycerides, total cholesterol, and LDL levels and significant increase in HDL level in response to n-3 supplementation in T2DM. These findings are similar to the results of previous meta-analyses [56][57][58][59]. Our sub-group analysis however also revealed that n-3 supplementation of greater than 1000 mg/d for more than 8 weeks can significantly improve the lipid profile in patients with T2DM.…”